N
The startup has developed an immunotherapy platform that utilizes engineered viral vectors to express tumor neoantigens, facilitating robust antitumor T-cell responses. This technology aims to enhance cancer-specific cellular immunity, addressing the need for more effective cancer treatments.
Basel, Switzerland
Updated 2 months ago
Funding
$157.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup has developed an immunotherapy platform that utilizes engineered viral vectors to express tumor neoantigens, facilitating robust antitumor T-cell responses. This technology aims to enhance cancer-specific cellular immunity, addressing the need for more effective cancer treatments.